ArticleBlood cancer journal2025

Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study.

Lambert Busque et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.